Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Triple negative breast cancer: the kiss of death

Open access
Jitariu, Adriana-Andreea, Cîmpean, Anca Maria, Ribatti, Domenico, Raica, Marius·2017·Oncotarget

Abstract

// Adriana-Andreea Jitariu 1 , Anca Maria Cîmpean 1 , Domenico Ribatti 2,3 and Marius Raica 1 1 Department of Microscopic Morphology/Histology, Angiogenesis Research Center, Victor Babeș University of Medicine and Pharmacy, Timișoara, Romania 2 Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy 3 National Cancer Institute “ Giovanni Paolo II”, Bari, Italy Correspondence to: Anca Maria Cîmpean, email: // Keywords : triple negative breast cancer, progression, metastases, therapeutic targets Received : February 14, 2017 Accepted : March 19, 2017 Published : April 07, 2017 Abstract One of the most controversial women malignancies, triple negative breast cancers (TNBCs) are critically overviewed here, being focused on data useful in clinical practice or to improve the therapy and patients survival. TNBCs “choose” young women and its “kiss” is, unfortunately deadly in most cases. Currently, few sparse data are available in literature concerning the origins of TNBC. Vasculogenic mimicry detected in TNBCs, seems to be determined by a population of CD133+ cells and may be stimulated by different pharmacological agents such sunitinib. Despite the fact that TNBCs do not usually metastasize through the lymphatic pathways, TNBCs may be characterized by lymphatic invasion and by an increased lymphatic microvascular density. If TNBCs treatment depends on the molecular profile of the tumor, the same statement may be postulated for TNBCs metastasis. Whether metastases have a similar phenotype as the primary tumor remains an enigma. Therefore, the question: ‘Could TNBC be subject to a standardized, unanimously accepted therapeutic strategy or is it strictly subclass-dependent?’ remains to be further investigated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.16938

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 173

Metadata

Authors
Jitariu, A.-A., Cîmpean, A. M., Ribatti, D., & Raica, M.
Venue
Oncotarget
Published
2017-04-07
Volume
8
Issue
28
Pages
46652-46662
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2604873860
Cited by
173
References
5
FWCI
6.55
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triple negative breast cancer: the kiss of death. https://app.cochat.ai/papers/10.18632/oncotarget.16938
The paper
Jitariu, A.-A., Cîmpean, A. M., Ribatti, D., & Raica, M. (2017). Triple negative breast cancer: the kiss of death. Oncotarget. https://doi.org/10.18632/oncotarget.16938

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.